CD28 and cancer: Similarly, there was extended PFS in other cancer patients with high expression of CD28 or low exosomal PD-L1 value (medianCD28, 2 vs. 9.2 months, P = 0.045; median PD−L1, 2 vs. 7.3 months, P = 0.066; Figure 6A).